26 articles
Moderna and Merck announced a breakthrough in mRNA cancer vaccine collaboration, marking the first late-stage success after over a century of failures. The vaccine showed efficacy in melanoma patients
Moderna and Merck announced positive data for their combination mRNA cancer vaccine intismeran and Keytruda in melanoma patients. The companies plan to present detailed study results at an upcoming in
The U.S. Treasury doubled bond buybacks to stabilize debt markets, while Moderna and Merck surged on a cancer vaccine breakthrough. Middle East conflicts reduced refining capacity, driving European di
The WHO announced 70,000 doses of Merck's Ervebo vaccine have reached the DRC for a Phase 3 trial targeting the Bundibugyo virus strain. This study aims to evaluate effectiveness against the newly cir
Asian stocks are set to rebound following US Treasury plans to boost bond buybacks, while commodities like oil and gold saw gains. Corporate highlights include Moderna and Merck's successful melanoma
Moderna and Merck reported positive Phase III trial results for a personalized mRNA melanoma vaccine, cutting recurrence risk by half. This breakthrough validates mRNA technology for oncology, with fu
Moderna and Merck announced successful late-stage trial results for their combined melanoma treatment, reducing cancer recurrence and spread. Following the data, Moderna shares surged 60% while Merck
Moderna shares surged over 60% after its vaccine combined with Merck's Keytruda met late-stage trial goals, while Brent crude hit a three-week high amid Middle East tensions. U.S. stock futures remain
Moderna and Merck announced that a personalized mRNA vaccine combined with Keytruda successfully slowed melanoma recurrence in late-stage trials. Detailed data will be presented at an upcoming medical
Major oil companies reported record refining profits driven by tight global supply, while pharmaceutical leaders Eli Lilly and Merck contributed to a strong quarterly earnings season amidst geopolitic
Global markets stabilize during U.S. earnings season, highlighting SpaceX results and oil price fluctuations amid Gulf tensions. Key data includes JOLTS job openings and earnings from pharmaceutical f
Asian stocks are poised to decline following a US chipmaker selloff, while crude oil prices rose amid Middle East tensions. Pharmaceutical leaders Merck and Eli Lilly announced regulatory approvals an
The FDA approved Merck’s Lipfendra, the first oral PCSK9 inhibitor for reducing LDL cholesterol. Analysts project annual sales exceeding $2 billion, marking a significant milestone for macrocyclic pep
A U.S. House committee launched an investigation into Merck and AbbVie over clinical trials in China, citing national security and ethical risks. Lawmakers require details on trial sites by July 17 am
Merck has agreed to acquire US life sciences firm Bio-Techne for $11.3 billion to bolster its portfolio in antibodies and cell therapy materials, with completion expected by 2027.
The U.S. government is fast-tracking veterinary drug approvals and funding to combat a screwworm outbreak threatening the cattle industry, despite staffing shortages. FDA authorized treatments from El
Merck process chemists Dani Schultz and LC Campeau launched a podcast to bridge the gap between academic and industrial chemistry, aiming to accelerate drug development innovation through closer colla
Merck executives are exploring molnupiravir as an Ebola treatment amid a worsening outbreak in the DRC. The company also noted potential applications for its existing Ebola vaccine technology against
Merck's cyclic peptide enlicitide secured an FDA priority voucher, aiming to become the first oral PCSK9 inhibitor. Forecasts exceed $2 billion in annual sales, underscoring a rising trend in peptide-
UK startup BioOrbit launched a unit to the International Space Station to produce ultra-pure protein crystals for self-injected cancer drugs via microgravity. Backed by £9.8m funding and partnerships
The WHO declared an Ebola public health emergency in DRC and Uganda, noting that currently approved vaccines like Merck's Ervebo are ineffective against the new strain. Case counts continue to rise wh
Regeneron shares fell 11.8% after its experimental fianlimab-cemiplimab combination failed to meet statistical significance in a late-stage melanoma trial against Merck's Keytruda. Despite a numeric i
Eli Lilly and Merck rose on drug sales forecasts, while Ford cited rising commodity costs; broader US indices climbed following strong tech earnings reports.
Merck beat Q1 sales expectations with Keytruda revenue rising 12% to $8 billion, offsetting acquisition charges that caused a net loss. The company raised its full-year profit guidance as investors fo
Merck & Co. agreed to acquire Terns Pharmaceuticals for $6.7 billion at $53 per share, representing a 31% premium, with the transaction expected to close within three months.
In June 2025, AICM unveiled a new mission emphasizing sustainable innovation. Executives from Olin, Merck, and SABIC discussed implementing Responsible Care to drive the petrochemical industry's green
ChemBrief